重组人血管内皮抑素联合化疗治疗难治性晚期恶性肿瘤  

Recombinant Human Endostatin Combined with Chemotherapy for Refractory Advanced Malignancies

作　　者：陈建清[1,2] 史涛[1,2] 吴晓安[1,2] 陈玉强[1,2] 叶煌阳[3] 许丽贞[1,2] 曾道林[1,2] 陈剑波[1,2] 

机构地区：[1]厦门大学附属成功医院 [2]解放军第174医院肿瘤中心,福建厦门361003 [3]厦门大学附属第一医院肿瘤内科,福建厦门361002

出　　处：《肿瘤基础与临床》2013年第4期314-316,共3页journal of basic and clinical oncology

基　　金：南京军区医学科技创新重点课题(编号:11Z021)

摘　　要：目的观察重组人血管内皮抑制素联合化疗治疗难治性晚期恶性肿瘤的疗效和毒副反应。方法58例难治性晚期恶性肿瘤患者接受重组人血管内皮抑制素与化疗的联合治疗,治疗后每2周期后评价疗效和生活质量,每周期后评价毒副反应。结果全组有57例患者可以评价客观疗效,58例均可进行毒副反应评价。PR 10例,SD 41例,PD 6例,客观有效率17.5%(10/57),疾病控制率89.5%(51/57)。生活质量改善21例(36.8%),稳定27例(47.4%),下降9例(15.8%)。化疗相关Ⅲ、Ⅳ度毒副反应包括白细胞减少15例(25.9%),血小板减少7例(12.1%),恶心、呕吐16例(27.6%)。另外有6例(10.3%)心电图异常。结论重组人血管内皮抑制素与化疗联合应用对难治性晚期恶性肿瘤有效,能提高患者的生活质量,毒副反应轻,安全性好。Objective To observe the efficacy and toxicities of recombinant human endostatin combined with chemotherapy for refractory advanced malignancies. Methods Recombinant human endostatin combined with chemotherapy were administrated to 58 patients with refractory advanced malignancies. The efficacy and quality of life were evaluated after 2 cycles. Toxicities were evaluated after 1 cycle. Results Fifty-seven cases were evaluable for efficacy among the total 58 cases thatwere capable of safety evaluation. Among the 57 evaluable cases, the 10 cases of PR,the 41 cases of SD,and the 6 cases of PD. The objective response rate was 17.5% （10/57） ,the disease control rate （DCR） was 89.5% （51/57）. The quality of life was improved on 21 cases （36.8%） ,stabled on 27 cases （47.4%）,and decreased on 9 cases （15.8%）. The chemotherapy-related toxicities grade Ⅲ and Ⅳ were leukopenia （ 15 cases ,25.9% ） , thrombocytopenia （7 cases, 12.1% ）, nausea and vomiting （ 16 cases, 27.6% ）. Abnormal electrocardiogram was observed in the 6 cases （ 10.3% ）. Conclusion Recombinant human endostatin combined with chemotherapy is effective and safe for refractory advanced malignancies, can improve the quality of life.

关 键 词：重组人血管内皮抑制素 晚期恶性肿瘤 化疗 

分 类 号：R730.53[医药卫生—肿瘤] R730.54[医药卫生—临床医学]